Semaglutide (GLP-1 Receptor Agonist)
Also Known AsOzempic · Wegovy · Rybelsus · NN9535
Developed by Novo Nordisk as a long-acting GLP-1 receptor agonist. Modified human GLP-1(7-37) with amino acid substitution (Aib at position 8) and a C-18 fatty diacid chain attached via a linker to Lys26, enabling albumin binding and ~7-day half-life.
How Semaglutide Works
GLP-1 Receptor Agonism
Binds and activates the GLP-1 receptor with 94% homology to native GLP-1. Stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, and slows gastric emptying.
Hypothalamic Appetite Regulation
Activates GLP-1 receptors in the hypothalamus and hindbrain, increasing POMC/CART neuron activity (satiety) and suppressing AgRP/NPY neuron activity (hunger). This central mechanism drives the majority of weight reduction effects.
Cardiovascular Signaling
GLP-1R activation in the cardiovascular system reduces systemic inflammation, improves endothelial function, and reduces atherogenic lipoprotein levels. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events.
Published Research
Obesity & Weight Management
StrongThe STEP trial program demonstrated mean weight reductions of 14.9% (STEP 1, 68 weeks) to 17.4% (STEP 5, 2 years) with semaglutide 2.4mg weekly. This represented the largest pharmacotherapy-induced weight loss in clinical trial history at the time of publication. Effects are attributed primarily to central appetite suppression via hypothalamic GLP-1R activation.
Type 2 Diabetes
StrongThe SUSTAIN program across 10+ trials demonstrated superior HbA1c reduction (1.5-1.8%) vs. comparators including other GLP-1RAs. Semaglutide 1.0mg weekly showed consistent glycemic benefits with additional cardiovascular and weight reduction advantages.
Cardiovascular Outcomes
StrongThe SELECT trial (n=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) in patients with overweight/obesity and established CVD, establishing a cardiovascular benefit independent of diabetes.
NAFLD/NASH
ModerateEmerging data from STEP-NASH and other studies demonstrate significant improvements in hepatic steatosis, NASH resolution, and fibrosis scores. GLP-1R activation reduces hepatic de novo lipogenesis and inflammation.
Addiction & Neuropsychiatric
EmergingObservational data and early-stage trials suggest potential effects on alcohol use disorder, substance cravings, and compulsive eating behaviors. Hypothesized mechanism involves mesolimbic dopamine reward circuit modulation via GLP-1R in the ventral tegmental area.
Safety Profile
Common adverse effects include nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%), primarily during dose escalation. Most GI effects are transient and dose-dependent. Black box warning for thyroid C-cell tumors in rodents (relevance to humans unclear). Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2.
Handling & Storage
Reconstitute lyophilized semaglutide with bacteriostatic water. The albumin-binding fatty acid modification ensures extended stability in solution. Store reconstituted solution at 2-8°C. Lyophilized powder stable at -20°C.
Peer-Reviewed Literature
- 1
Once-weekly semaglutide in adults with overweight or obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al.
- 2
Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
- 3
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6)
Marso SP, Bain SC, Consoli A, et al.
- 4
A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome PN, Buchholtz K, Cusi K, et al.
Semaglutide FAQ
What is semaglutide?
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It shares 94% structural homology with native human GLP-1 and has been engineered with an albumin-binding fatty acid chain for a ~7-day half-life, enabling once-weekly dosing in clinical applications.
What are the main research applications of semaglutide?
Semaglutide is the subject of extensive clinical research across obesity, type 2 diabetes, cardiovascular disease prevention, NAFLD/NASH, and emerging neuropsychiatric applications. The STEP, SUSTAIN, and SELECT trial programs represent some of the largest clinical datasets for any metabolic compound.
What is the difference between semaglutide and retatrutide?
Semaglutide is a single-receptor agonist targeting only GLP-1R. Retatrutide is a triple agonist targeting GLP-1R, GIPR, and GCGR simultaneously. In clinical trials, retatrutide has demonstrated higher mean weight reduction (~24%) compared to semaglutide (~17%), likely due to additive effects from GIP and glucagon receptor activation.
How should research-grade semaglutide be stored?
Lyophilized semaglutide should be stored at -20°C for long-term preservation. Once reconstituted with bacteriostatic water, store at 2-8°C (refrigerator). The fatty acid modification provides enhanced stability compared to unmodified GLP-1 analogs.
Semaglutide Products
All compounds 99%+ purity, verified by Janoshik Analytical. GMP-manufactured lyophilized powder.
The weight loss revolution — the same molecule in Ozempic that helps millions lose 15-20% of body weight by silencing food cravings and resetting appetite at the brain level.
- Lose 15-20% of body weight without willpower or starvation
- Completely eliminates food noise and constant cravings
Extended semaglutide supply for serious weight loss — 6mg for longer protocols. The compound behind the biggest weight loss transformation in medical history.
- Double-dose for sustained weight loss programs
- 15-20% body weight reduction documented in trials
Explore Related Research
Retatrutide 12mg
12mgThe most powerful weight loss compound ever studied — triple-receptor agonist that achieved 24% body weight loss in trials, outperforming semaglutide by hitting THREE metabolic pathways.
- Triple-action weight loss — targets GLP-1, GIP, AND glucagon receptors
- 24% body weight loss in trials — MORE than semaglutide
Cagrilintide
5mgThe semaglutide amplifier — a long-acting amylin that pairs with GLP-1 drugs to supercharge weight loss. Part of the CagriSema combination that's the next breakthrough.
- Long-acting amylin analog for appetite suppression
- Pairs with semaglutide for enhanced weight loss (CagriSema)
Mazdutide
5mgDual-action fat burner — hits both GLP-1 and glucagon receptors for aggressive fat loss, with special effectiveness against dangerous liver fat and NAFLD.
- Dual GLP-1/glucagon agonist for aggressive fat loss
- Particularly effective against liver fat (NAFLD)
Disclaimer: This monograph is provided for educational and research purposes only. G26x Peptides products are sold exclusively as research chemicals. They are not intended for human consumption, therapeutic use, or as dietary supplements. All research should be conducted in compliance with applicable laws and institutional review board protocols. Information presented here is sourced from published peer-reviewed literature and does not constitute medical advice.